News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Shaheenah Dawood: Phase 2 RAMP201 Trial Leading to FDA Accelerated Approval of Avumetinib and Defactinib
Shaheenah Dawood/LinkedIn
Jul 13, 2025, 13:27

Shaheenah Dawood: Phase 2 RAMP201 Trial Leading to FDA Accelerated Approval of Avumetinib and Defactinib

Shaheenah Dawood, Consultant Medical Oncologist at Mediclinic Middle East, shared a post on LinkedIn:

“Phase 2 RAMP201 (ENGOTov60/GTG-UK/GOG3052)trial leading to FDA accelerated approval avumetinib and defactinib now published.”

Title: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Authors: Susana N. Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley J. Monk, Andrew Clamp, Emily Prendergast, Ana Oaknin, Kari Ring, Nicoletta Colombo, Robert W. Holloway, Manuel Rodrigues, Hye Sook Chon, Charlie Gourley, Alessandro D. Santin, Premal H. Thaker, Christine Gennigens, Gregg Newman, Erin Salinas, Hagop Youssoufian, Kathleen N. Moore, Stephanie Lustgarten, David M. O’Malley, Toon Van Gorp, Rachel N. Grisham

Read Full Article on Journal of Clinical Oncology.

Shaheenah Dawood

More posts featuring Shaheenah Dawood on OncoDaily.

Alessandro D. Santin Ana Oaknin Andrew Clamp Bradley J. Monk cancer Carol Aghajanian Charlie Gourley Christine Gennigens David M. O'Malley Els Van Nieuwenhuysen Emily Prendergast Erin Salinas Gregg Newman Hagop Youssoufian Hye Sook Chon Kari Ring Kathleen N. Moore Manuel Rodrigues Nicoletta Colombo OncoDaily Oncology Premal H. Thaker Rachel N. Grisham Robert W. Holloway Stephanie Lustgarten Susana N. Banerjee Toon Van Gorp Véronique D’Hondt
Special Coverage
Drugs
Jul 13, 2025, 13:27
Shaheenah Dawood: Phase 2 RAMP201 Trial Leading to FDA Accelerated Approval of Avumetinib and Defactinib
Opinion
Jul 13, 2025, 13:25
Agrima Mian: ASH Committee on Communications Summer 2025 Meeting
Blog
Jul 13, 2025, 13:20
Abstract Deadline Extended for the IASLC 2025 Asia Conference on Lung Cancer
Blog
Jul 13, 2025, 13:18
Wafaa M Rashed: The 9th Cohort of the Policy Advocacy in Genetics and Genomics Course
Blog
Jul 13, 2025, 13:07
Vineet Datta: The Only Limit to the Realisation of Our Dream is Our Doubts of Today
Blog
Jul 13, 2025, 13:06
Fabio Ynoe de Moraes: From Wimbledon to Oncology - The Evolution of Selective Excellence
Insight
Jul 13, 2025, 12:56
ESO-OncoDaily Educational Workshop in Breast and GI Oncology
Blog
Jul 13, 2025, 12:51
Hung Trinh: Bispecific and Trispecific Antibodies - The Next Trend for Various Therapeutic Areas with Combination Synergies
Blog
Jul 13, 2025, 12:41
There is a Great Cost to Silencing Science - The Lancet Group
Blog
Jul 13, 2025, 12:32
Laura Bukavina: Start Living Not Just Surviving Your Diagnosis
Insight
Jul 13, 2025, 12:29
Hassan R. Hashmi: Are We Entering a New Era Where Physical Activity Becomes an Adjuvant Modality in Immuno-Oncology?
Blog
Jul 13, 2025, 12:24
Runcie C.W. Chidebe: CONSORT 2025 Statement - Updated Guideline for Reporting Randomized Trials